China's Oral Healthcare Market Expands, Increasing Demand for Dental Injection Needles

China’s oral healthcare market is growing at an annual rate of 12% as of 2024, driven by increasing health awareness and an aging population. as reported by China’s Centre for Medical Device Evaluation (CMDE). CMDE republished the article titled "Introduction to the clinical use and risks of dental injection needles" from the China Instrument Review dated February 13, 2025.

The market for dental anesthesia devices has surpassed 1.8 billion yuan, with disposable dental injection needles accounting for over 35% of total sales. The article highlights the market opportunity for dental manufacturers generally and for dental injection needles in particular in the China market.

Clinical Practice Trends: Precision Anesthesia Drives Product Upgrades

The latest clinical guidelines released by CMDE state that the selection of dental injection needles needs to consider the injection depth, tissue density, and patient anatomical characteristics comprehensively.

The current mainstream clinical needs show three major trends:

1. The popularization of nerve block techniques: The proportion of deep anesthesia such as the inferior alveolar nerve has increased to 42%, driving the demand for 32mm long needles and 25G/27G large inner diameter products.

2. The rise of comfortable treatment: The application of ultra-short needles (12mm) in superficial injections in the palate has increased, with the market annual growth rate of 30G fine needles reaching 28%.

3. Upgrading of safety standards: The clinical attention to the rigidity and anti-bending of the needle body has increased, with 90% of medical institutions requiring suppliers to provide test reports in accordance with YY/T0587-2023.

Opportunities for international companies: Developing high-rigidity needle tube products for high-difficulty anesthesia scenarios in China (such as puncture of large mandible), and providing clinical operation training at the same time, can quickly establish a differentiated advantage.

Regulatory Compliance Key Points: NMPA Approval Core Focus

Notice 2025-01, the registration of dental injection needles need to focus on the following key links:

1. Argumentation of performance indicators and clinical relevance

Specification adaptability: Need to prove the match between product length/inner diameter and the claimed indications (such as infiltration/block anesthesia) through ex vivo tissue puncture tests.
Rigidity-comfort balance: In accordance with GB/T18457, submit test data with needle tube bending displacement ≤3mm, and correlate with clinical pain score reports.
Biocompatibility: The residual amount of ethylene oxide must be less than 50% of the limit value of ISO10993-7, with priority given to passivated stainless steel materials.

2. Construction of risk control system

Needle breakage prevention: Need to clearly warn in the product instructions "Do not insert the entire needle into the tissue", and design needle hub color marks to indicate the maximum insertion depth.
Doctor training program: It is recommended to be equipped with a VR puncture simulation system to reduce the risk of complications caused by improper operation (the incidence rate needs to be controlled at <0.03%).

Common pain points for international companies: The rejection rate of direct transposition of clinical data from Europe and America for declaration is as high as 67%, mainly because no adaptive verification has been carried out for the differences in the mandibular bone morphology of Chinese patients.

Future Trends: Intelligence and New Material Innovation

China's medical device review authority predicts that from 2026, the following technologies will lead market iteration:

Smart sensing needle hub: Real-time feedback on puncture depth and pressure to reduce the risk of needle breakage (three domestic companies have entered clinical testing).
Biodegradable coating: Reduce tissue damage and improve patient comfort (a European brand's clinical trial in China shows a 40% reduction in pain index).
AI-assisted needle selection system: Automatically recommends needle types based on CBCT data, which has been piloted in 15% of top-tier hospitals.

Further Information

To read the original China's medical device review authority released the latest clinical guidelines, please click here. If you are a dental manufacturer with questions about how long it takes or how much it costs to register your product for the China market, please contact Cisema.